Two hundred thirty cases of malignant non‐Hodgkin's lymphomas were reclassified in a retrospective study according to the New Working Formulation for Clinical Usage of the NCI as compared to the Rappaport and Kiel classifications. The reproducibility for the individual schemes this study was 81% (Rappaport), 79% (Kiel), and 85% (New Working Formulation). In keeping with the results of the NCI international study,1 all lymphomas were subdivided into 3 prognostic groups: (1) low‐grade malignancy (6.0 years median survival); (2) intermediate‐grade malignancy (3.5 years median survival); and (3) high‐grade malignancy (1.4 years median survival). The NCI‐proposed New Working Formulation for Clinical Usage is thus recommended as practical and unprejudicing classification scheme for general application; however, its usefulness as tool for translating one classification scheme into another appears limited.